Close
CDMO Safety Testing 2026
Novotech
Production & Manufacturing

TPI to start test runs at JCM manufacturing plant

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Business & Industry

AddParts Secures Funding for Pharma Manufacturing Resilience

AddParts, a UK-based technology company focused on improving operational...
Press Releases

Made Smarter Advances AI in Manufacturing with New Toolkit

A new initiative from Made Smarter is aiming to...
Drug Research

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.
- Advertisement -

China-based drug manufacturer Tianyin Pharmaceutical (TPI) is set to start test run at its 250-ton Jiangchuan Macrolide facility (JCM) for good manufacturing practice (GMP) certification process.
The company will conduct the test runs by the end of this month to investigate whether the plant is maintaining GMP.Additionally, the company will also verify its performance, efficiency, reliability and safety of the Azithromycin API manufacturing at JCM.Following the successful completion of the test runs the company will initiate the GMP certification process.

Latest stories

Previous article
Spanish regulators give manufacturing license to Midatech Biogune
Next article
Aenova, SkyePharma in manufacturing alliance

Related stories

Business & Industry

AddParts Secures Funding for Pharma Manufacturing Resilience

AddParts, a UK-based technology company focused on improving operational...
Press Releases

Made Smarter Advances AI in Manufacturing with New Toolkit

A new initiative from Made Smarter is aiming to...
Drug Research

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.
Drug Research

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

About us

World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives. . . Read More

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Copyright © 2010-2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »
MORE STORIES
Cyclic peptide screening

Fujifilm Advances Drug Discovery with New Cyclic Peptide Screening Platform

Pharma Manufacturing

AddParts Secures Funding for Pharma Manufacturing Resilience